Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exicure, Inc.    XCUR

EXICURE, INC.

(XCUR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

EXICURE, INC. : Change in Directors or Principal Officers (form 8-K)

share with twitter share with LinkedIn share with facebook
09/18/2020 | 05:07pm EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 18, 2020, David S. Snyder informed Exicure, Inc. (the "Company") of his intention to resign as the Company's Chief Financial Officer and Secretary, effective September 30, 2020 (the "Departure Date"). Mr. Snyder will continue to serve in these roles through the close of business on the Departure Date. Mr. Snyder's departure is not related to any disagreement regarding the Company's operations, policies or practices. The Company has commenced a search for a new Chief Financial Officer.

The Company's Chief Executive Officer, David A. Giljohann, Ph.D., has been appointed to serve as the Company's interim principal financial officer and corporate secretary effective as of immediately after the close of business on the Departure Date until a new principal financial officer is appointed. The Company is not aware of any transaction or relationship involving Dr. Giljohann requiring disclosure under Item 404(a) of Regulation S-K. Dr. Giljohann's compensation has not changed and is not expected to change as a result of this appointment.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses


share with twitter share with LinkedIn share with facebook
All news about EXICURE, INC.
10/19EXICURE : Announces Phase 1b Poster Presentation at The Society for Immunotherap..
BU
10/05EXICURE : to Present at the Chardan Virtual 4th Annual Genetic Medicines Confere..
BU
10/01EXICURE, INC. : Entry into a Material Definitive Agreement, Creation of a Direct..
AQ
10/01EXICURE : Secures Debt Facility for Up to $25.0 Million
BU
09/18EXICURE, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/16EXICURE, INC. : Regulation FD Disclosure, Other Events, Financial Statements and..
AQ
09/16EXICURE : Presents Promising Interim Results from Ongoing Phase 1b/2 Trial of Ca..
BU
08/25EXICURE : Announces a Virtual KOL Meeting to Discuss Preliminary Phase 1b Effica..
BU
08/12EXICURE, INC. : Reports Second Quarter 2020 Financial Results and Corporate Prog..
BU
08/05EXICURE, INC. : to Present at the BTIG Virtual Biotechnology Conference 2020
BU
More news
Financials (USD)
Sales 2020 17,8 M - -
Net income 2020 -19,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -6,77x
Yield 2020 -
Capitalization 134 M 134 M -
Capi. / Sales 2020 7,54x
Capi. / Sales 2021 19,1x
Nbr of Employees 47
Free-Float 76,7%
Chart EXICURE, INC.
Duration : Period :
Exicure, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXICURE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 10,50 $
Last Close Price 1,54 $
Spread / Highest target 1 069%
Spread / Average Target 582%
Spread / Lowest Target 355%
EPS Revisions
Managers
NameTitle
David A. Giljohann CEO, CFO, Secretary & Director
Timothy P. Walbert Chairman
Matthias Schroff Chief Operating Officer
Douglas E. Feltner Chief Medical Officer
Chad A. Mirkin Director
Sector and Competitors
1st jan.Capitalization (M$)
EXICURE, INC.-46.15%134
GILEAD SCIENCES, INC.-7.73%75 173
REGENERON PHARMACEUTICALS56.00%61 638
VERTEX PHARMACEUTICALS-5.39%53 956
WUXI APPTEC CO., LTD.59.09%37 810
BEIGENE, LTD.81.76%27 304